Karlsen, W.; Akily, L.; Mierzejewska, M.; Teodorczyk, J.; Bandura, A.; Zaucha, R.; Cytawa, W.
Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers 2024, 16, 1990.
https://doi.org/10.3390/cancers16111990
AMA Style
Karlsen W, Akily L, Mierzejewska M, Teodorczyk J, Bandura A, Zaucha R, Cytawa W.
Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers. 2024; 16(11):1990.
https://doi.org/10.3390/cancers16111990
Chicago/Turabian Style
Karlsen, William, Lin Akily, Monika Mierzejewska, Jacek Teodorczyk, Artur Bandura, Renata Zaucha, and Wojciech Cytawa.
2024. "Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons" Cancers 16, no. 11: 1990.
https://doi.org/10.3390/cancers16111990
APA Style
Karlsen, W., Akily, L., Mierzejewska, M., Teodorczyk, J., Bandura, A., Zaucha, R., & Cytawa, W.
(2024). Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers, 16(11), 1990.
https://doi.org/10.3390/cancers16111990